Drugs / SQZ-eAPC-HPV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05357898 | Mar 2022 → Nov 2023 | — | SQZ Biotechnologies | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SQZ-eAPC-HPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05357898 ↗ |
| Modality | Cell therapy | “Enhanced antigen presenting cells (eAPC) cell therapy” NCT05357898 ↗ |